StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3039% below fair value
$10.29−0.02 (-0.19%)

Close on Nov 19, 2026Market cap $629.10MP/E –Yield –

Janux Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Janux Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$41.93M. For fiscal 2025 it was -$83.28M. The highest annual figure on record is -$4.37M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$83.28M–
FY2024Dec 31, 2024-$44.17M–
FY2023Dec 31, 2023-$52.43M–
FY2022Dec 31, 2022-$49.37M–
FY2021Dec 31, 2021-$18.46M–
FY2020Dec 31, 2020-$4.37M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.28M–
Q1 FY2026Mar 31, 2026-$12.61M–
Q4 FY2025Dec 31, 2025-$28.65M–
Q3 FY2025Sep 30, 2025-$12.95M–
Q2 FY2025Jun 30, 2025-$24.29M–
Q1 FY2025Mar 31, 2025-$17.40M–
Q4 FY2024Dec 31, 2024-$16.77M–
Q3 FY2024Sep 30, 2024-$2.26M–
Q2 FY2024Jun 30, 2024-$10.12M–
Q1 FY2024Mar 31, 2024-$15.03M–
Q4 FY2023Dec 31, 2023-$10.42M–
Q3 FY2023Sep 30, 2023-$12.18M–
Q2 FY2023Jun 30, 2023-$15.63M–
Q1 FY2023Mar 31, 2023-$14.20M–
Q4 FY2022Dec 31, 2022-$13.97M–
Q3 FY2022Sep 30, 2022-$15.93M–
Q2 FY2022Jun 30, 2022-$6.97M–
Q1 FY2022Mar 31, 2022-$12.49M-330.9%
Q4 FY2021Dec 31, 2021-$11.65M–
Q3 FY2021Sep 30, 2021-$5.93M–
Q2 FY2021Jun 30, 2021-$6.28M–
Q1 FY2021Mar 31, 2021$5.41M–
Q4 FY2020Dec 31, 2020-$1.63M–
Q3 FY2020Sep 30, 2020-$1.08M–

More Janux Therapeutics figures

See a number that looks wrong?